Reblozyl (luspatercept-aamt) / BMS, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   40 Trials   40 Trials   1659 News 


«12...6789101112131415161718»
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Review, Journal:  Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. (Pubmed Central) -  Dec 16, 2020   
    Our review will discuss luspatercept, a transforming growth factor (TGF)-Beta ligand trap, the first new Food & Drug Administration (FDA)-approved treatment in MDS in over a decade. We will explore the different TGF-Beta ligand traps that have been developed for a number of diseases, with a focus on myeloid malignancies.
  • ||||||||||  sotatercept (ACE-011) / Acceleron, BMS, Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Review, Journal:  Activin Receptor-Ligand Trap for the Treatment of β-thalassemia: A Serendipitous Discovery. (Pubmed Central) -  Nov 18, 2020   
    In this review, we describe in extenso the TGF-β pathway, as well as the molecular and biological basis of activin receptors ligand traps, focusing on their role in various β-thalassemia experimental models. The most recent results from clinical trials on sotatercept and luspatercept will also be reviewed.
  • ||||||||||  Epogen, Procrit (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Hakko Kirin
    [VIRTUAL] An Observational Study to Collect and Assess Tissue Samples from Subjects with One of Three Neoplastic Conditions (ANSWer) () -  Nov 5, 2020 - Abstract #ASH2020ASH_4998;    
    The correlation between clinical response and drug sensitivity will be assessed using the area under the receiver-operator curve (AUROC) and bootstrapping to test for significance. A generalized estimation equation model will be used to identify associations between additional exploratory biomarkers, such as somatic mutations identified via NGS, andex vivosensitivity to various drug classes within specific treatment cohorts.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    [VIRTUAL] Anti-GDF11Treatment of β-Thalassemia Intermedia Mice Does Not Improve Erythropoiesis (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3404;    
    Luspatercept (Acvr2b(L79D)-Fc) is a novel treatment for transfusion-dependent β-thalassemia patients that improves erythropoiesis independent of erythropoietin...Taken together, GDF11 is not involved in erythropoiesis but GDF8 may have a minor role in the regulation of ineffective erythropoiesis. Given the small effect of anti-GDF8 on erythropoiesis compared to Acvr2b(L79D)-Fc, we conclude that either there is another target or several targets of Acvr2b(L79D)-Fc driving ineffective erythropoiesis, or that Acvr2b(L79D)-Fc efficacy is due to it altering the overall BMP/GDF/Activin ligand and receptor balance.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    [VIRTUAL] SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level (Channel 15 (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3133;    
    Of note, the growth differentiation factor 11 receptors ACVR1B, TGFBR1, and ACVR1C were not expressed at any step of erythroid differentiation, which challenges this factor’s role as a target of luspatercept-induced differentiation of late-stage erythroblasts...1c), which suggests that failure to eradicate or genetically correct SF3B1MT stem cells leads to disease relapse. In conclusion, our results elucidate how SF3B1MT molecularly affect distinct stages of erythropoiesis and have implications for developing approaches that achieve lasting hematological remission in patients with MDS-RS.
  • ||||||||||  Epogen, Procrit (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Hakko Kirin, Reblozyl (luspatercept-aamt) / Acceleron, BMS
    [VIRTUAL] The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2662;    
    P3
    Recent studies of epoetin alfa and darbepoetin alfa have demonstrated efficacy among patients with LR-MDS, but the patient population in whom a clinically significant effect is seen may be limited (Fenaux P, et al...Exclusion criteria include prior use of ESAs (≤ 2 doses of prior epoetin alfa permitted if ≥ 8 weeks from randomization date and sEPO confirmed as ≤ 500 U/L), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), unless given for the treatment of febrile neutropenia; disease-modifying agents (e.g. lenalidomide), or hypomethylating agents; and presence of del(5q) cytogenetic abnormality...Key secondary endpoints include duration of RBC-TI, change in Hb levels, achievement of HI-E response per International Working Group (IWG) 2006 criteria, and safety. The COMMANDS trial is registered at ClinicalTrials.gov (NCT03682536) and EudraCT (number 2017-003190-34).
  • ||||||||||  rapamycin topical (PTX-022) / Palvella Therapeutics, Ligand
    [VIRTUAL] Rapamycin (Sirolimus) and Rap-536 Increase Red Blood Cell Parameters through Distinct Mechanisms in Wild-Type and Thalassemic Mice (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_1734;    
    RAP-536 increased and rapamycin decreased overall reticulocyte levels and immature reticulocyte relative percentages in whole reticulocyte populations in the blood of WT mice, suggesting that RAP-536 and rapamycin have different mechanisms of action through which they increase RBC and Hb levels. Altogether, these preclinical results provide a rationale for combining rapamycin, and potentially other mTOR inhibitors, with luspatercept to treat anemia associated with beta-thalassemia.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Journal:  Luspatercept to treat β-thalassemia. (Pubmed Central) -  Oct 27, 2020   
    Despite recent impressive advances in understanding human normal and abnormal erythropoiesis, there are few new drugs and limited pharma research focusing on ineffective erythropoiesis. This review will discuss recent advances in understanding normal and pathological erythropoiesis that represent the background to discuss pharmacology, toxicology, efficacy, safety and effectiveness of this new drug for the treatment of human β-thalassemia.
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Trial initiation date:  Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients (clinicaltrials.gov) -  Oct 26, 2020   
    P1/2,  N=50, Not yet recruiting, 
    This review will discuss recent advances in understanding normal and pathological erythropoiesis that represent the background to discuss pharmacology, toxicology, efficacy, safety and effectiveness of this new drug for the treatment of human β-thalassemia. Initiation date: Sep 2020 --> Jan 2021
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Development of novel therapies in MDS (ATİLLA YALÇIN HALL) -  Sep 23, 2020 - Abstract #EHOC2020EHOC_68;    
    Luspatercept inhibits exaggerated TGF-β signaling that underlies a molecular basis on ineffective hematopoiesis...Oral AZA (CC-486 and ASTX727) and guadecitabine, and combinations of HMAs with pevonedistat and venetclax are under development. Further, combination of HMA with checkpoint inhibitors such as nivolumab and ipilimumab is promising especially for therapy-naïve patients.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Clinical, Review, Journal:  Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. (Pubmed Central) -  Sep 16, 2020   
    In this Review, we summarize evidence that overactivation of SMAD2/3 signaling pathways in MDSs causes anemia due to impaired erythroid maturation. We also describe the basis for biological activity of activin receptor ligand traps, novel fusion proteins such as luspatercept that are promising as erythroid maturation agents to alleviate anemia and related comorbidities in MDSs and other conditions characterized by impaired erythroid maturation.